therapy is also associated with weight lossand improvement in cardiovascular riskfactors, including blood pressure and se-rum lipid proÔ¨Åles (16). Furthermore, theglucose-dependent mechanisms of actionof exenatide minimize the risk of hypo-glycemia. GLP-1R agonists have recentlybeen added to the American Diabetes As-sociation and European Association forthe Study of Diabetes consensus algo-rithm for the treatment of type 2 diabetesas an option after the addition of met-formin in patients in whom body weightand hypoglycemia risk are concerns (1). Exenatide BID is administered within the 60-min period before the morningand evening meals and primarily exerts itspharmacodynamic effects on glucose